Ludwig Enterprises, Inc. is poised for a significant transformation as FOXO Technologies Inc. aims to acquire a controlling interest in the company through a series of stock purchase agreements. This development is notable not only for Ludwig but also for the medical laboratory services sector, where competition is fierce and strategic acquisitions can lead to major shifts in market dynamics.

On October 29, 2026, FOXO Technologies filed a Schedule 13D with the SEC, detailing its plans to acquire 5,000,000 shares of Convertible Preferred Stock from two sellers, The Thomas E. Terwilliger Revocable Trust and Vasaio Capital, Inc. This acquisition would grant FOXO approximately 74.9% of the voting power in Ludwig, significantly increasing its influence over the company.

Background

Ludwig Enterprises, Inc. operates within the medical laboratory services industry, classified under SIC 8071. The company is listed on the OTC under the ticker symbol LUDG. Recent filings indicate that Ludwig has been navigating a challenging environment, having ceased compliance as a reporting company as of August 19, 2026.

What the Filing Says

The Schedule 13D filing reveals that FOXO Technologies intends to acquire the preferred shares to gain voting control of Ludwig. The filing states, "FOXO entered into the Purchase Agreements... for the purpose of acquiring voting control of the Issuer." If the transactions close, FOXO would be able to elect or remove directors of Ludwig and influence significant corporate decisions.

Impact

This acquisition could have profound implications for Ludwig's operations and strategic direction. If the transaction is completed, FOXO will hold a majority of the voting power, allowing it to steer Ludwig's future initiatives, including the development of its Revealia platform. The filing also notes that the interim CEO of Ludwig has offered to resign, which may lead to further changes in leadership, potentially including Mark White from FOXO stepping in as interim CEO.

What's Next

The acquisition is still pending, with several conditions outlined in the Purchase Agreements that must be met before closing. These include the approval of FOXO's common stock for listing on The Nasdaq Stock Market and satisfactory due diligence regarding Ludwig's capitalization. The filing does not specify a timeline for these developments, but it indicates that the sellers may terminate the agreements if the listing and related public offering are not completed within 120 days.